PDCD1 and melanoma: The ECHO-301 confirmatory phase 3 study in patients with advanced melanoma was designed to determine the effectivity of epacadostat (an IDO/TDO inhibitor) in combination with pembrolizumab (anti PD-1 antibody); this combination showed a better overall response rate than that observed with anti-PD-1 alone.